Neurocrine starts CAH drug trial in children under age 4

July 1, 2026 4:05 PM

Neurocrine Biosciences (NASDAQ: NBIX) has initiated a Phase 2 clinical study to evaluate the safety and tolerability of crinecerfont in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found